ArticlePharmaceuticals (Basel, Switzerland)2022

Rosiglitazone Does Not Show Major Hidden Cardiotoxicity in Models of Ischemia/Reperfusion but Abolishes Ischemic Preconditioning-Induced Antiarrhythmic Effects in Rats In Vivo.

Bennet Y Weber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.